ZELANDOPAM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H15NO4
Molecular Weight	273.2839
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(C=C1O)[C@@H]2CNCC3=C2C=CC(O)=C3O

InChI

InChIKey=FULLEMQICAKPOE-JTQLQIEISA-N

InChI=1S/C15H15NO4/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20/h1-5,10,16-20H,6-7H2/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C15H15NO4
Molecular Weight	273.2839
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9559326
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/9809482 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/9885db9d9ee078055567f91ba45eabde.html | http://adisinsight.springer.com/drugs/800002584

YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
dopamine receptor D1 3 Target ID: 489110.0 Gene Symbol: DRD1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1425944	Agonist 2678		2.9 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Congestive heart failure 54 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9559326 http://adisinsight.springer.com/drugs/800002584	Primary	Phase II 1132	Unknown Approved Use Unknown
Acute renal failure 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9809482 https://www.ncbi.nlm.nih.gov/pubmed/12586214	Primary	Preclinical	Unknown Approved Use Unknown
Nephrosis 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15740732	Preventing	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats.	2005 Mar 7	15740732

Patents

Sample Use Guides

In Vivo Use Guide

Dog: 0.1-3 ug/kg/min

Route of Administration: Intravenous

In Vitro Use Guide

YM-435 displayed a capacity to promote cAMP formation in bovine retina when ATP/GppNHp was present. The maximally stimulated level of CAMP induced by YM 435 (210% of the controls; ATP/GppNHp only, no agonist added), was attained with 10 uM agonist. The EC50 value of YM-435-induced cAMP formation was 1.97 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:30:42 GMT 2023` Edited by `admin` on `Fri Dec 15 16:30:42 GMT 2023`
Record UNII	IR6XYD8SAX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZELANDOPAM

Official Name

English

zelandopam [INN]

Common Name

English

Zelandopam [WHO-DD]

Common Name

English

(-)-(S)-4-(3,4-DIHYDROXYPHENYL)-1,2,3,4-TETRAHYDRO-7,8-ISOQUINOLINEDIOL

Systematic Name

English

SELANDOPAM

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66884